Background During the last three decades tremendous progress has been made in the discovery and development of a lot of new molecules in many pharmaceutical areas. These families of real innovative treatment comprise "originator" molecules (first molecule released, which can be under patent or with expired patent), as well a "generic" version of those originator molecules, whose patent has expired. Usually the patent expires 15-20 years after the creation of the originator molecule. Main objective This research focuses on the effects of the arrival of generic and or therapeutic competitors on the market, in terms of impact on the market share and prices.
Introduction
During the last three decades, tremendous progress has been made in the discovery and development of a lot of new molecules in many pharmaceutical areas. The therapeutic groups of cardiovascular medicines such as inhibitors of angiotensin-converting enzyme (ACE inhibitors), sartans and statins, are good examples of the aforementioned development and creation of therapeutic families (Fyhrquist and Saijonmaa 2008; Raizada and Ferreira 2007) .
These families of real innovative treatment are comprised of "originator" molecules (first molecule released, which can be under patent or have an expired patent), as well "generic" versions of those originator molecules whose patent has expired. Usually the patent expires 15-20 years after the creation of the originator molecule. These last products (what we call "generics") have the same chemical structure and have been proven to be essentially similar in bioavailability (Morgan et al. 2005) .
To give an example, a molecule, the ramipril, in the family of ACE inhibitors has been launched by the pharmaceutical laboratory Sanofi Aventis under the name of Triatec. When the patent of this product expired, a competitor, the pharmaceutical laboratory QualiMed, launched another version of same product in terms of molecule and effects; thus, a generic, called Ramipril Qualimed came onto the market. However, within the same therapeutic group, MSD had already launched enalapril under the name of Renitec, which is a "therapeutic competitor" with a small variation in chemical structure.
Following the same approach of modification of the first molecule, perindopril, trandolapril, fosinopril and so on were later developed and, thus, the whole therapeutic family started to expand.
Conceptual framework and literature review
The generics create competition and drive medicine prices down (Lee 2004) . Many studies show in fact that when a new medicinal product (a new molecule corresponding to an originator or the same molecule corresponding to a generic after the patent expiration) appears on the pharmaceutical market, it affects the market trends as well as prices of the existing generic and/or therapeutic competitors (Dirach 2000) . To what extent and for how long time this takes place depends on the specific characteristics of the national market, the laws concerning the generics and the pharmaceutical companies' policy. A common perception is that the original medicinal product ensures new therapeutic options for severe diseases, while the generic medicines support the sustainability of healthcare provision and contribute to maintaining control over the pharmaceutical expenditure (Scott Morton FM 1999) .
Some countries use laws to promote the prescription and the delivery of generics, which leads to a decrease in health expenditures. Studies focusing on the market policy of the pharmaceutical manufacturers consider that every new product, within the same therapeutic class, is characterised by simultaneous entry of competitors rather than sequential (Scott Morton FM 1999) . Basically, what this means is that the expiration of a product patent is accompanied by the simultaneous entry, sometimes the same day, of a different generic. Models have been created to calculate the aggregated demand and supply features, influencing the generic pharmaceutical market (Gascon et al. 2007) .
During the last two decades, a reference pricing approach was developed, which began to be used in a lot of European countries (Huttin 2002) . The reference prices are established after an international or national comparison of prices of the generic or therapeutic alternatives (MestreFerrandiz 2003) . The reference price could be either the lowest or the average price within the compared group of products (Mrazek 2002) . This policy stimulates research in the area of price comparison and analysis of the factors influencing price changes, as does the generics' policy and competition.
Cardiovascular medicines are of particular interest for studying the competition between originators and generics. They are one of the leading therapeutic classes on the global pharmaceutical market today, with more or less 10% of the market sales in value (WHO 2007) . For this particular reason, this class represents a big interest for the pharmaceutical manufacturers and we currently can find new innovative products and new generics within it. This interest is also shared by health authorities who, in wanting to control the increase of expenditures, analyse their prescriptions and their usage, creating national rules regarding price control.
In this cardiovascular category of treatment, three groups of therapeutics present a bigger interest due to the presence of innovative molecules and the arrival of generics: the families of inhibitors of angiotensin-converting enzyme (ACE inhibitors), sartans and statins (Luno et al. 2005; Rossi 2006; Levy 2005) .
The ACE inhibitors appeared with the discovery of the captopril molecule in 1975 that was considered as a breakthrough, due to its novel mechanism of action and revolutionary development process. Nowadays, this therapeutic group includes 16 different molecules with a similar structure, from which some of them, lots of generic products have originated (Rossi 2009 ). Currently, only two molecules are still under patent protection.
The sartans (also called "angiotensin receptor blockers" or "angiotensin II receptor antagonists") modulate the rennin-angiotensin-aldosterone system and thus lead to a decrease in blood pressure. The tetrazole group is a main part of the chemical structure of losartan, irbesartan, olmesartan, candesartan and valsartan. In addition, losartan, irbesartan, olmesartan, candesartan and telmisartan include one or two imidazole groups. Within the group of sartans, valsartan and losartan have expired patents and generics available on the market.
The statins are lipid lowering agents containing the firstmarketed INN lovastatin, which was followed on the market soon after by simvastatin (Stossel 2008) . The statins therapeutic group is composed of six molecules from which four have expired patents.
Main objective
The aim of this study is to analyse the changes in the drug usage and prices in these three pharmaco-therapeutic groups, acting on the cardiovascular system, on the Bulgarian market between the years [2005] [2006] [2007] (INN) . To summarise the differences between the packages, the usage was recalculated in milligrams for every INN during the particular year observed.
The information for the drug prices was gathered from the official register of the Ministry of Health for all authorised trade names of observed medicines (Ministry of Health 2005 -2007 . Then, the prices were recalculated to establish the price per milligram for every dosage form for all medicines within the group of products under the same INN. To calculate the mean price per INN and per milligram, a descriptive statistic was applied.
To test the first hypothesis, we first applied the Kolmogorov Smirnov (K-S) test towards the sales data during the observed years. To test the second hypothesis, we first performed a twoway ANOVA analysis to evaluate the statistically significant differences between the prices of active substances, per milligram, for the products within each therapeutic group and during the observed years. If there was a difference established, we then performed a one-way ANOVA analysis to evaluate them per INN followed by an analysis comparing them to other therapeutic alternatives.
Results
Out of all collected medicinal products in the therapeutic class of ACE inhibitors, we found three INNs with generics: the enalapril, lisinopril (during 2005-2007) and the generics for ramipril appeared during the third year of observation (2007) . In the therapeutic class of statins we also found four INNs with generics: simvastatin, pravastatin, atorvastatin and the lovastatin. In the last therapeutic class studied, the sartans, we found one INN with a generic, the losartan. The other INNs within these three therapeutic groups are considered as therapeutic competitors. All these results are in the table in Appendix. Some of the cells are marked with "0" due to the lack of sales data in the National Health Insurance Fund's database for the particular year observed.
Analysis of the market share of products
In the product class of ACE inhibitors, the enalapril in milligrams is the leader of the class with 93.1% of the market share in 2005, which is when we begun our study. We can say that the fast growth rate of the therapeutic group and introduction of two different new molecules within the class lead to a decrease in the market share of enalapril during 2006 of 4.5% and during 2007 of 2.24% (Fig. 1) . On the other hand, the market share of the therapeutic competitors has slowly and permanently increased every year; thus, taking part of the enalapril market share.
It is also necessary to point out that after the introduction of the generic competitors to lisinopril in 2006, its market share increased with a bigger percentage (from 2.34% in 2005 to 3.65% in 2006) than the share of the other therapeutic competitors within the group and this increase is still continuing, even after the exclusion in the following year of one of the products.
In the product class of sartans, the biggest market share in 2005 was that of telmisartan, probably because of the promotional price of the originator. In the second year, the only one product with a generic version (losartan) increased its market share almost 6 times; thus, taking a leading position within the group. The market dynamic in proportions of INNs sold within the group of sartans is mostly evident in comparison with the previous group, but we can suppose that these changes are contributed mainly to the active market development of the products within the group (Fig. 2) .
The product class of statins is the most dynamic in terms of changes of generic and therapeutic competitors. In this group, we observed that after the increase of the number of generic competitors under the same INN, the relative market share of the INN increased-as is the case for simvastatin. We can consider that the introduction of new generics did not deprive the sales data of the originator immediately, but, in general, contributed to the accumulation in market share of a particular group of INNs. In this group we also observed that the introduction of a new product affects the sales data of competitors, as is the case with the inclusion of rosuvastatin (Fig. 3) .
After applying the Kolmogorov Smirnov test, we observed that there is a statistically significant difference among the sales data during 2006 and 2005, as (Table 1) . To test the differences among the INNs' sales data, the z-test analysis was applied. The results of the z-test analysis confirm that for almost all the products, except for the perindopril and trandolapril in the class of ACE inhibitors, and irbesartan from class of sartans, the changes in the market share are statistically significant (Table 2 ). For all of these three products there is no generic competitor. So we can conclude that the introduction of generics changes the market share of the INNs and contributes to the changes in the share of the therapeutic groups. The changes in the market share products without generics could be explained with the marketing policy of the companies-a fact that was not explored in this study. Thus our first hypothesis is confirmed.
Analysis of price changes
Concerning the prices, all of them decreased during the observed period from 2005 to 2007; however, it was mainly due to the changes in regulation (Appendix; drug price For the group of ACE inhibitors, the two-way ANOVA analysis confirms that the prices per milligram differed among the observed products (p<0.05), but did not differ statistically significant during the years for the whole group (p>0.05; Table 3 The one-way ANOVA analysis revealed significant differences (p<0.05) in prices throughout the study for lisinopril only (Table 4) . It is necessary to point out that the mean price decreased in the year 2007, when one of the generics, the most expensive one, was excluded from the database.
The statines group included 6 INNs with 20-29 dosage forms per year. In this group, we also did not find significant price differences among the years (p>0.05), Table 3 ). By applying multiple comparisons, the difference among lovastatin and rosuvastatin was evaluated as statistically significant. No differences among the prices for particular INNs were observed (Table 4) . For the group of sartans, we also found, through the twoway ANOVA analysis, that the prices per milligram differ among the observed products (p<0.05), but did not differ significantly during the observed years for the whole group (p>0.05; Table 3 ). Multiple comparisons among the INNs within the therapeutic groups revealed significant price differences between telmisartan and eprosartan. No differences between the prices for particular INNs were evaluated separately (Table 4) .
The results from two way and one way ANOVA analysis revealed that there are no statistically significant changes in the prices of the observed INNs, except for lisinopril, but there are significant price differences between the therapeutic competitors within the groups. Thus our second hypothesis is not fully confirmed,
Discussion, limitations and further research
The cardiovascular pharmaceutical market characteristics are of importance for the national markets for a lot of reasons such as: e.g., their permanently growing usage, progress in new molecules discovery, changes in life expectancy of the population, creation of the national rules for price control, and cost containment measures. Although we do observe a dynamic national market of cardiovascular medicines that corresponds to world trends, the competition is mostly evident at the therapeutic groups level than at the generic level.
Our results confirm those of similar studies-that the generic competition, in general, changes the market in the observed country. These changes benefit the generic products and decrease the medicines' prices. The generic competition is not regulated in the country and this fact could influence negatively our study because it does not correspond to world trends (Ministry of Health 2005 -2007 .
Furthermore, our results, that the creation of a sustainable generic pharmaceutical market requires active regulatory and marketing measures at all levels (including incentives for manufactures, physicians, and dispensers), confirms that of other publications (Simoens and de Coster 2006; Adriaen et al. 2008) . It is not only sufficient to shorten the marketing authorisation process for generic medicines at a European level, but every country should have its own regulatory measures as well.
Our study possesses some limitations in terms of the fact that we compare the mean prices per milligram and not per defined daily dose (DDD), which is more therapeutically compatible. Despite the fact that DDD is established in milligrams for most of the medicines, we consider that in the future such analysis should be done for the changes in prices per DDD. Comparison of the market share and prices in milligrams has its own reasoning for international market tender purposes (Al-Abbadi et al. 2009; Karam 2010; Zaheer et al. 2007) , as well as for reference prices comparison. Such a price comparison per milligram of active substance is also regularly performed by the Management science for health and World health organisation when they publish the International Drug Price Indicator Guide and all prices are shown per milligrams of active substance (Frye 2007) . Some countries are using the generics' price per milligrams in the process of establishing the lowest price per product within the reimbursement system (Mrazek 2002) .
Other authors consider (WHO 2003) that, if medicine utilisation is given in terms of grams of active ingredients, drugs with low potency will account for a larger fraction of the total than drugs with high potency, and that the combined products may also change their market figure. In our study, we did not observe any combination, so our figures could not be affected by such utilisation data. We also did not observe significant changes in the prices per milligram for pharmaceuticals with different potencies; thus, this was also not a case for consideration.
The international price comparison per milligrams of active substance could be used by regulatory authorities. Grootendorst et al. (2001) analysed the impact of referenced-based pricing on nitrates usage and cost reduction by also using the cost per milligram. A similar approach was found useful in the case of comparison of pharmaceutical prices for particular therapeutic groups (Wang et al. 2008) , which is also the case in our study. The fact that we could not establish strong evidence supporting our second hypothesis could be explained by the short period of observation and slow entrance of generic medicines in the positive drug list of the National Health Insurance Fund. Generic competitors were only found for 8 out of 20 compared INNs and for 4 of them-ramipril, pravastatin, atorvastatin, losartan-only one competitor was found, which limits the evaluation of the impact of generic competition on existing prices. We did not analyse the way the pharmaceutical laboratories communicate with the prescribers, which can also have an effect on the market.
Further studies should be organised to evaluate the changes in prices over a longer period, when more generic competitors will be available in the country. The national policy on generic medicines is also of importance because it stimulates pharmaceutical price competition.
Conclusion
There are two main conclusions from our study. The first one is that for those therapeutic groups that include a lot of similar molecules, it is important to consider the competition between the molecules and not only the generic entrance. Originating pharmaceutical companies seem to compete among themselves at a therapeutic level and with generic companies at a price level.
The second conclusion is that the introduction of generic medicines did not affect the mean market prices immediately, which means the market needs more than 3 years of stronger competition to benefit. From the managerial point of view, it is necessary to point out that if the government wants to benefit from the generic drug policy, and thus to reduce pharmaceutical prices in the country, it should create a stronger supporting environment affecting all the participants in the pharmaceutical sector in the country.
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